Skip to main content
. 2020 Jun 17;11:1190. doi: 10.3389/fimmu.2020.01190

Figure 1.

Figure 1

Human Group 1 ILCs expressed Eomes differentially during NSCLC progression. (A) Gating for identification of Group 1 ILC subsets in peripheral blood of NSCLC patients. Group 1 ILCs were gated as CD45+ Lineage (CD3, CD19, CD11b, CD11c)−c-Kit−CRTH2−; ILC1s were further gated as CD127+CD56− and NK cells as CD127−CD56+ (B) Percentage of Eomeslo subset gated over CD45+ Lineage (CD3, CD19, CD11b, CD11c)−c-Kit− CRTH2−T-bet+ cells at early stage (Stage I and II) vs. late stage (III and IV). Cancer progression is accompanied with increase in frequency of cells expressing lower Eomes levels (C) Quantification of Eomes expression in Group 1 ILC subsets, viz, ILC1, and NK cells. Peripheral blood NK cells showed higher Eomes levels compared to circulating ILC1s (D) Quantification of T-bet expression in Group 1 ILC subsets, viz, ILC1, and NK cells. Peripheral blood NK cells showed higher T-bet levels compared to circulating ILC1s. MFI is Mean Fluorescence Intensity, n = 16 for stage I, n = 4 for stage II, n = 4 for stage III, n = 7 for stage IV. Data are presented as mean ± s.e.m.; significance was tested using unpaired two tailed students' t-test.